Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Myasthenia Gravis × inebilizumab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 2 Recurrence 1 Myasthenia Gravis 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1

Interventions

Rituximab 2 Hizentra 2 zilucoplan 1 thymoglobulin 1 rozanolixizumab 1 rhoA GTP-Binding Protein 1 prednylidene 1 inebilizumab 1 gamma-Globulins 1 efgartigimod alfa 1 eculizumab 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 apraclonidine 1 Sternotomy 1 Prednisone 1 Peripheral Blood Stem Cell Transplantation 1 Methotrexate 1 Melphalan 1 Immunoglobulins, Intravenous 1 HBM9161 1 Fluid Therapy 1 Etoposide 1 Cytarabine 1 Carmustine 1 CK-2017357 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06987539 2026-03-16

THYME

Amgen

Phase 2 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡